Evidence map›Paper›PMID 27066980›Full record

ArticleInfection2016

Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

K de With, F Allerberger, S Amann, P Apfalter, H-R Brodt, T Eckmanns, M Fellhauer, H K Geiss, O Janata, R Krause and 11 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06293677 (Upwards Initial Adjustment of Wide-Spectrum Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Suspected Augmented Renal Clearance), which is not on this map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06293677 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

Upwards Initial Adjustment of Wide-Spectrum Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Suspected Augmented Renal Clearance: A Randomized Controlled Trial With Therapeutic Drug Monitoring

TypeinterventionalSponsorCentre Hospitalier Universitaire VaudoisRan2024 to 2026Enrolled30ConditionsFebrile NeutropeniaArmsDosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem, Standard dosages of piperacillin-tazobactam or meropenem
3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Frameworks to support evidence-informed decision-making in public health and infectious disease prevention and control: a scoping review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  8. Users' experience of frameworks to support evidence-informed decision-making in public health: a scoping review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. An in-depth analysis of antimicrobial prescription quality in 10 non-university hospitals, in southwest Germany, 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 20 institutions in 3 countries.

K de WithDivision of Infectious Diseases, University Hospital Carl Gustav Carus at the TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Katja.deWith@uniklinikum-dresden.de.
F AllerbergerDivision Public Health, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
S AmannHospital Pharmacy, Munich Municipal Hospital, Munich, Germany.
P ApfalterInstitute for Hygiene, Microbiology and Tropical Medicine (IHMT), National Reference Centre for Nosocomial Infections and Antimicrobial Resistance, Elisabethinen Hospital Linz, Linz, Austria.
H-R BrodtDepartment of Infectious Disease Medical Clinic II, Goethe-University Frankfurt, Frankfurt, Germany.
T EckmannsDepartment for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
M FellhauerHospital Pharmacy, Schwarzwald-Baar Hospital, Villingen-Schwenningen, Germany.
H K GeissDepartment of Hospital Epidemiology and Infectiology, Sana Kliniken AG, Ismaning, Germany.
O JanataDepartment for Hygiene and Infection Control, Danube Hospital, Vienna, Austria.
R KrauseSection of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria.
S LemmenDivision of Infection Control and Infectious Diseases, University Hospital RWTH Aachen, Aachen, Germany.
E MeyerInstitute of Hygiene and Environmental Medicine, Charité, University Medicine Berlin, Berlin, Germany.
H MittermayerInstitute for Hygiene, Microbiology and Tropical Medicine (IHMT), National Reference Centre for Nosocomial Infections and Antimicrobial Resistance, Elisabethinen Hospital Linz, Linz, Austria.
U PorscheDepartment for Clinical Pharmacy and Drug Information, Landesapotheke, Landeskliniken Salzburg (SALK), Salzburg, Austria.
E PresterlDepartment of Infection Control and Hospital Epidemiology, Medical University of Vienna, Vienna, Austria.
S ReuterClinic for General Internal Medicine, Infectious Diseases, Pneumology and Osteology, Klinikum Leverkusen, Leverkusen, Germany.
B SinhaDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
R StraußDepartment of Medicine 1, Gastroenterology, Pneumology and Endocrinology, University Hospital Erlangen, Erlangen, Germany.
A Wechsler-FördösDepartment of Antibiotics and Infection Control, Krankenanstalt Rudolfstiftung, Vienna, Austria.
C WenischMedical Department of Infection and Tropical Medicine, Kaiser Franz Josef Hospital, Vienna, Austria.
W V KernDivision of Infectious Diseases, Department of Medicine, Freiburg University Medical Center, Freiburg, Germany.
Krankenhaus der Elisabethinen · ATAustrian Agency for Health and Food Safety · ATCharité - Universitätsmedizin Berlin · DEGoethe University Frankfurt · DEKaiser-Franz-Josef-Spital · ATKlinikum Leverkusen · DEKrankenanstalt Rudolfstiftung der Stadt Wien · ATMedical University of Graz · ATMedical University of Vienna · ATMünchen Klinik · DERobert Koch Institute · DERWTH Aachen University · DESalzburger Landeskliniken · ATSana Klinikum · DESchwarzwald-Baar Klinikum · DEUniversität für Weiterbildung Krems · ATUniversitätsklinikum Erlangen · DEUniversity Hospital Carl Gustav Carus · DEUniversity Medical Center Freiburg · DEUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the time of increasing resistance and paucity of new drug development there is a growing need for strategies to enhance rational use of antibiotics in German and Austrian hospitals. An evidence-based guideline on recommendations for implementation of antibiotic stewardship (ABS) programmes was developed by the German Society for Infectious Diseases in association with the following societies, associations and institutions: German Society of Hospital Pharmacists, German Society for Hygiene and Microbiology, Paul Ehrlich Society for Chemotherapy, The Austrian Association of Hospital Pharmacists, Austrian Society for Infectious Diseases and Tropical Medicine, Austrian Society for Antimicrobial Chemotherapy, Robert Koch Institute. MATERIALS AND

methodsA structured literature research was performed in the databases EMBASE, BIOSIS, MEDLINE and The Cochrane Library from January 2006 to November 2010 with an update to April 2012 (MEDLINE and The Cochrane Library). The grading of recommendations in relation to their evidence is according to the AWMF Guidance Manual and Rules for Guideline Development.

conclusionThe guideline provides the grounds for rational use of antibiotics in hospital to counteract antimicrobial resistance and to improve the quality of care of patients with infections by maximising clinical outcomes while minimising toxicity. Requirements for a successful implementation of ABS programmes as well as core and supplemental ABS strategies are outlined. The German version of the guideline was published by the German Association of the Scientific Medical Societies (AWMF) in December 2013.

Indexed as

Anti-Infective AgentsPharmacy Service, HospitalPractice Guidelines as TopicQuality of Health CareCommunicable DiseasesDrug ResistanceGermanyHumansInappropriate PrescribingAnti-Infective AgentsABSAntibiotic stewardshipAntimicrobial resistanceGuidelineQuality of careRational use

Identifiers

PMID27066980
PMCPMC4889644
OpenAlexW2340076839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.